Skip to content

Homoeopathy in obstructive sleep apnea

Homoeopathic medicines in Obstructive sleep apnea A double blind randomized placebo-controlled pilot trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084056
Enrollment
30
Registered
2025-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G473- Sleep apnea

Interventions

Intervention1: Homoeopathic Medicines: The active intervention group will be given homoeopathic medicine (selection, potency, dose, repetition will be as per homoeopathic principles). Intervention is

Sponsors

Director General, Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants suffering from OSA as per International Classification of Sleep Disorders (ICSD-3-TR) OSA diagnostic criteria. 2. Participants must voluntarily agree not to use CPAP once enrolled in the study 3. Gender: Male, female and other. 4. Age: 18 to 65 years 5. Literate participants ability to read english or bengali and/or hindi. 6. Willing to give informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Participants suffering from severe OSA and undergoing treatment with CPAP were excluded from the study. 2. Participants enrolled in the study if urgently required CPAP after consultation with the expert shall be dropped out from the study. 3. Participants suffering from uncontrolled systemic illness or life-threatening infections affecting quality of life. 4. Pregnant and lactating mother 5. Participants already undergoing homoeopathic treatment for any chronic diseases within the last 3 months. 6. Substance abuse and/or dependence and self-reported immune-compromised states. 7. Patients with major psychiatric diseases or unstable mental illnesses, such as Schizophrenia, Major Depressive Disorder, and bipolar disorder, will be excluded after consultation with our expert consultant. Additional exclusions may apply if deemed necessary by the consultant.

Design outcomes

Primary

MeasureTime frame
1. Polysomnography test 2. SAQLI scoreTimepoint: 1. At baseline, and at 12 months of study 2. At baseline, and then every month up to 12 months of the study.

Secondary

MeasureTime frame
Not applicableTimepoint: Nil

Countries

India

Contacts

Public ContactDr Laijun Nahar

Central Council for Research in Homoeopathy

laijun786@gmail.com7980274752

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026